THE FIRST FDA-APPROVED TRASTUZUMAB BIOSIMILAR¹
STAY FOCUSED
ON TREATING HER2+ CANCER
Biocon Biologics is committed to being your long-term biosimilars partner.
So you can remain committed to what matters most.
OGIVRI is highly similar to Herceptin®, and is backed by an oncology biosimilars company you can trust.2-5

Demonstrated to be as safe and effective as Herceptin2-5

First trastuzumab biosimilar with OS data at 36 months3
Primary endpoint met: equivalent ORR at Week 24 compared with Herceptin

Multiple vial options give flexibility to practices when choosing dosage2
OGIVRI is highly similar to Herceptin®, and is backed by an oncology biosimilars company you can trust.2-5

Demonstrated to be as safe and effective as Herceptin2-5

First trastuzumab biosimilar with OS data at 36 months3
Primary endpoint met: equivalent ORR at Week 24 compared with Herceptin

Multiple vial options give flexibility to practices when choosing dosage2
SUPPORT
FOR YOU AND YOUR PATIENTS
From the moment you prescribe OGIVRI, Biocon Biologics provides you with the resources and support you need to help your patients get started on their therapy.
Copay Assistance
Access to OGIVRI for commercially insured patients with a copay as low as $0.*
Coding and Billing
Information regarding applicable coding for OGIVRI and its administration (OGIVRI has been assigned a product billing code of Q5114).
BenefitS Investigation
Information on patient-specific insurance coverage requirements and patient cost-sharing aspects such as copay, coinsurance, and out-of-pocket maximum.
Prior Authorization/ Reauthorization Assistance
Requirement and submission details assistance, status tracking, and help with payer-specific forms.
Coverage/Claim Appeal
Assistance
Appeal requirement verification and appeal status/resolution tracking.
Insurance AND Alternate Coverage
Patient insurance plan enrollment verification and identification of state programs, third-party charitable foundations, or other coverage options.
Patient Assistance
Medication that may be available free of charge to patients without insurance coverage for OGIVRI who cannot afford their medication.†
PATIENT BROCHURE
An informative guide for patients new to OGIVRI.
*Eligibility requirements apply.
†Eligibility requirements apply based on residency, income, and other factors. Contact My Biocon BiologicsTM for more information.
Copay Assistance
Access to OGIVRI for commercially insured patients with a copay as low as $0.*
BenefitS Investigation
Information on patient-specific insurance coverage requirements and patient cost-sharing aspects such as copay, coinsurance, and out-of-pocket maximum.
Coverage/Claim Appeal
Assistance
Appeal requirement verification and appeal status/resolution tracking.
Patient Assistance
Medication that may be available free of charge to patients without insurance coverage for OGIVRI who cannot afford their medication.†
Coding and Billing
Information regarding applicable coding for OGIVRI and its administration (OGIVRI has been assigned a product billing code of Q5114).
Prior Authorization/ Reauthorization Assistance
Requirement and submission details assistance, status tracking, and help with payer-specific forms.
Insurance AND Alternate Coverage
Patient insurance plan enrollment verification and identification of state programs, third-party charitable foundations, or other coverage options.
PATIENT BROCHURE
An informative guide for patients new to OGIVRI.
*Eligibility requirements apply.
†Eligibility requirements apply based on residency, income, and other factors. Contact My Biocon BiologicsTM for more information.
MY BIOCON BIOLOGICSTM SPECIALISTS ARE HERE TO HELP
The My Biocon Biologics Patient Support Program offers assistance to individuals prescribed OGIVRI.
Our specialists can provide support for everything from coverage and claim concerns to copay and financial assistance questions*
Help is available Monday-Friday 9 AM-8 PM ET—just call 1-833-695-2623
Enroll your patients through the My Biocon Biologics portal*
Download the
Download the My Biocon Biologics enrollment form.
MY BIOCON BIOLOGICSTM
SPECIALISTS ARE HERE TO HELP
The My Biocon Biologics Patient Support Program offers assistance
to individuals prescribed OGIVRI.
Our specialists can provide support for everything from coverage and claim concerns to copay and financial assistance questions*
Help is available Monday-Friday
9 AM-8 PM ET—just call
1-833-695-2623
Enroll your patients through the My Biocon Biologics portal*
Download the My Biocon Biologics enrollment form.
*Eligibility requirements apply.
BIOSIMILARITY
YOU CAN COUNT ON
Totality of evidence for OGIVRI is based on similarity in analytical, clinical, and extrapolation data to Herceptin.2
DEMONSTRATED EQUIVALENCE when compared to Herceptin in efficacy and safety in the Phase 3 HERITAGE trial of patients with HER2+ metastatic breast cancer.3,4
SIMILAR SAFETY with no new safety signals observed in long-term follow-up and no significant difference in LVEF between OGIVRI and Herceptin.3,4
LVEF=left ventricular ejection fraction.
OGIVRI IS AVAILABLE In Single-DOSE and Multi-dose Vials
Multiple dosage forms help reduce waste and let you choose the right dosage form for your practice.2
150 mg single-dose vial
NDC: 83257-001-11
420 mg multi-dose vial
NDC: 83257-004-12
- OGIVRI has been assigned the product-specific billing code Q5114
- Available in full-line and specialty channels
- Store OGIVRI vials in the refrigerator at 35 to 46 °F (2 to 8 °C)

Please see Full Prescribing Information for the dosing of OGIVRI.

A FLEXIBLE ONCOLOGY
PARTNER

Biocon Biologics provides more than just biosimilars—let us flex our capabilities to meet your unique oncology needs.


With a portfolio of oncology biosimilars on the market and in our pipeline, we are committed to the long-term sustainability of biosimilars technology.
REFERENCES
1. FDA approves first biosimilar for the treatment of certain breast and stomach cancers. FDA News Release. December 1, 2017. Last reviewed January 16, 2018. Accessed August 13, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-certain-breast-and-stomach-cancers 2. OGIVRI. Prescribing information. Biocon Biologics Inc; 2024. 3. Rugo HS, Pennella EJ, Gopalakrishnan U, et al. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2021;188(2):369-377. 4. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 2017;317(1):37-47. 5. US Food and Drug Administration. Biosimilars: review and approval. Last updated December 13, 2022. Accessed March 11, 2024. https://www.fda.gov/drugs/biosimilars/review-and-approval